| Name | Title | Contact Details |
|---|---|---|
Matt Walnock |
Chief Technology Officer | Profile |
Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers choice in the treatment of inflammation and related conditions.
RELATIENT mobilizes existing, real-time healthcare data to automatically build relationships and promote loyalty with the healthcare consumer, drive compliance and adherence, boost revenue, lower costs, and build lasting relationships like no other Patient Engagement and Messaging platform available today. Compatible with most EHR/PM system on the market, RELATIENT boosts productivity by completely automating necessary outreach in the categories of Appointments, Patient Payments, Health Maintenance, Satisfaction Surveys, Self-Scheduling, and Demand messaging to patients. Reach out to us, you`ll be glad you did!
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.
Cyanotech Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Kailua Kona, HI. To find more information about Cyanotech Corporation, please visit www.cyanotech.com